U.S. Stocks Poised for Upside in the Week After 24 November 2025

Disclaimer: This blog article is for informational purposes and does not constitute financial advice. Past performance is not a guarantee of future results. Always conduct your own due diligence or consult a qualified financial adviser before making investment decisions.

Market context

U.S. markets head into the final week of November with thin liquidity because of the Thanksgiving holiday. Despite a rough preceding week for technology stocks, fund flows show investors still buying equities, particularly large‑ and small‑cap names. Important macro data arrive Tuesday (Producer Price Index, retail sales and consumer confidence) and Wednesday (durable‑goods orders and jobless claims), while Black Friday will provide an early read on consumer demand blog.portfolioparrot.com. This environment means that company‑specific catalysts — earnings results, guidance and sector momentum — can have an outsized impact on individual stocks.

Stocks to watch

The following five U.S. stocks have strong momentum, positive catalysts, or both heading into the week beginning 24 November 2025. Each company is listed with reasons why its shares could continue trending higher.

1 — Guardian Pharmacy Services (GRDN)

Business: Guardian Pharmacy Services is a long‑term‑care pharmacy operator that combines local clinical expertise with national scale. The company completed its IPO in September 2024 and focuses on providing medications and consulting services to assisted‑living and skilled‑nursing facilities.

Why it may move higher:

1. Strong earnings beat and raised guidance. In its third‑quarter 2025 report, Guardian’s revenue jumped 20 % year‑over‑year to $377 million, driven by a 13 % increase in residents served. The company beat analysts’ EPS expectations ($0.25 vs. consensus of $0.24) and raised its full‑year 2025 revenue guidance to $1.43–$1.45 billion and its adjusted EBITDA guidance to $104–$106 million, up from prior ranges of $1.39–$1.41 billion and $100–$102 million. fool.com. CEO Fred Burke said the results demonstrate “the power of our model”, fool.com.
2. Investor enthusiasm. The shares gained more than 7 % intraday after the earnings release and outperformed the broader market. WallStreetZen rates GRDN as a Strong Buy and notes that analysts from Truist Securities raised their price target to $34 following the earnings beat, citing “brisk overarching secular demand drivers” in the long‑term‑care niche. Guardian is the fourth‑highest‑rated stock in its medical‑care‑facility industry wallstreetzen.com.

Catalysts for the coming week: With few competing earnings announcements during the holiday-shortened week, investors may continue to focus on Guardian’s recent guidance raise and the long‑term‑care demographic tailwind. Any further analyst upgrades or momentum in healthcare leadership could support the blog.portfolioparrot.com

2 — Wayfair Inc. (W)

Business: Wayfair is a leading e‑commerce retailer specialising in furniture and home goods through its Wayfair, Joss & Main and AllModern brands.

Why it may move higher:

1. Blow‑out third‑quarter results and analyst upgrades. Wayfair shares surged nearly 24 % after reporting a strong third‑quarter 2025, with revenue growth, robust order momentum and the highest EBITDA margins in four years. Piper Sandler raised its price target to $125, and Bank of America upgraded the stock to Buy; UBS and Argus also increased their price targets following the results. Analysts praised Wayfair’s ability to gain market share and maintain cost discipline despite a challenging consumer environment.
2. Strategic initiatives and Black Friday tailwinds. The company has expanded its physical store footprint and logistics network, and it launched extensive Black Friday and holiday promotions beginning on 20 November at stocktotrade.com. Simply Wall St notes that Wayfair’s share price has jumped 112.6 % year‑to‑date and 130.9 % over the past year, with strategic partnerships in home‑improvement and logistics fueling investor optimismsimplywall.st. Although there has been some volatility, the company’s discounted cash‑flow analysis suggests the stock could be undervalued by over 50 % simplywall.st.

Catalysts for the coming week: Holiday‑shopping commentary will dominate the week, and Wayfair’s early Black Friday data could indicate whether the company continues to capture share. Analysts’ recent upgrades and strong momentum may attract traders looking for consumer‑discretionary exposure during the holiday season.

3 — Tutor Perini Corporation (TPC)

Business: Tutor Perini is a diversified construction and civil‑engineering company that builds large infrastructure projects across its Civil, Building and Specialty Contractor segments.

Why it may move higher:

1. Record results and improved guidance. In the third quarter of 2025, Tutor Perini posted adjusted EPS of $1.15, beating the Zacks consensus estimate of $0.96 by nearly 20 %, and swung from an adjusted loss of $1.92 per share a year earlier. Revenue climbed 31 % year‑over‑year to $1.42 billion, also beating expectations. The company raised its 2025 adjusted EPS outlook to $4.00–$4.20 from $3.65–$3.95nasdaq.com and expects EPS in 2026–2027 to be significantly above the revised guidance on nasdaq.com.
2. Growing backlog and infrastructure momentum. Tutor Perini’s backlog rose 54 % year‑over‑year to $21.6 billion, reflecting strong project awards and opportunities in civil infrastructure. The stock jumped 14.8 % in after‑hours trading following the earnings release. WallStreetZen highlights the stock’s earnings momentum and notes that top analyst Alex Rygiel initiated coverage with a Strong Buy rating and an $85 price target wallstreetzen.com. Tutor Perini is currently the seventh highest‑rated stock in the engineering and construction industry, according to wallstreetzen.com.

Catalysts for the coming week: Although Tutor Perini does not report earnings this week, investors may continue to price in rising infrastructure spending and watch for additional project awards. Any positive commentary on public infrastructure funding in the macro data or news flow could benefit the stock.

4 — Okeanis Eco Tankers (ECO)

Business: Okeanis Eco Tankers operates a fleet of eco‑efficient tankers transporting crude oil and petroleum products. It focuses on Suezmax and very large crude carrier (VLCC) vessels.

Why it may move higher:

1. Massive earnings beat on high tanker rates. The company’s third‑quarter 2025 earnings were $0.77 per share, smashing the Zacks consensus estimate of $0.29 by 165 % according to Nasdaq.com. Revenue of $59.95 million topped expectations by 26 %nasdaq.com. Analyst Liam Burke of B. Riley Securities maintained a Strong Buy rating with a $45 target, noting that stable Suezmax and high VLCC spot rates should allow Okeanis to maintain its performance advantage wallstreetzen.com.
2. Strong analyst backing despite mixed ratings. WallStreetZen reports that Okeanis has a Strong Buy consensus from four analysts, with two Strong Buy and two Buy ratings wallstreetzen.com. The stock has gained about 65.8 % year‑to‑date, outperforming the S&P 500’s 16.4 % gain. nasdaq.com. However, Zacks notes that negative estimate revisions ahead of the earnings release gave the stock a Rank #4 (Sell), meaning volatility is possible at nasdaq.com. Traders should monitor tanker‑rate trends and earnings‑estimate revisions.

Catalysts for the coming week: Shipping stocks can be sensitive to oil‑price moves and macroeconomic data. Updates on oil inventories or geopolitical developments could lift tanker rates. Positive commentary from analysts following the earnings beat may also support the shares.

5 — Eli Lilly & Co. (LLY)

Business: Eli Lilly is a global pharmaceutical company best known for its diabetes and obesity drugs, including tirzepatide sold as Mounjaro (for type 2 diabetes) and Zepbound (for obesity).

Why it may move higher:

1. Weight‑loss drug boom. On 21 November 2025, Eli Lilly became the first drugmaker to reach a $1 trillion market value as its stock rallied more than 35 % this year, reuters.com. The rally has been fuelled by explosive demand for weight‑loss drugs; sales of tirzepatide (Mounjaro/Zepbound) exceeded Merck’s Keytruda to become the world’s best‑selling drug. reuters.com. In the most recent quarter, Lilly earned over $10.09 billion from its obesity and diabetes portfolio, more than half of its total revenue. reuters.com. The company raised its annual revenue forecast by more than $2 billion on surging demand, Reuters.com.
2. Pipeline and policy tailwinds. Analysts expect continued growth as Lilly scales production, expands distribution and prepares to launch an oral obesity drug called orforglipron, reuters.com. A deal with the U.S. administration aims to expand access to weight‑loss drugs to roughly 40 million potential U.S. patients. reuters.com. BMO Capital Markets analysts note that Lilly’s valuation reflects confidence in the durability of its metabolic‑health franchise. With investors looking for alternatives to over‑owned AI stocks, Deutsche Bank suggests Lilly could resemble the “Magnificent Seven” again. reuters.com.

Catalysts for the coming week: Investors will watch for any regulatory or reimbursement updates that affect obesity drugs, as well as macro data that influence healthcare stocks’ defensive appeal. Momentum from the weight‑loss narrative and a scarcity of competing earnings releases could keep Lilly’s shares bid.

Summary table

Stock (Ticker)Recent catalysts it could move Guardian Pharmacy Services (GRDN)Q3 2025 revenue up 20 %, EPS beat; raised full‑year revenue & EBITDA guidance fool.com. New IPO with strong earnings momentum and raised guidance; analysts raised price targets and rated it a Strong Buy. wallstreetzen.com.comWayfair (W)Q3 results far exceeded expectations; revenue growth and order momentum drove a ~24 % post‑earnings rally stockstotrade.com. Multiple analyst upgrades (Piper Sandler, Bank of America, UBS) and Black Friday promotions support continued momentum. stockstotrade.com stockstotradecom Tutor Perini (TPC)Q3 EPS $1.15 vs. $0.96 est.; revenue up 31 %; backlog up 54 %; raised 2025 EPS guidance. nasdaq.com.Infrastructure spending and a strong project pipeline position the construction firm for continued growth; analysts call it one of the best earnings‑momentum stories. wallstreetzen.com Okeanis Eco Tankers (ECO)Q3 EPS $0.77 vs. $0.29 est., revenue beat by 26 %; strong Suezmax and VLCC rates. nasdaq.com. Tanker‑rate strength and analyst enthusiasm (Strong Buy ratings, $45 target) could drive shares higher wallstreetzen.com, though Zacks warns of estimate‑revision risk. nasdaq.com. Eli Lilly (LLY). Became the first drugmaker to hit $1 trillion valuation amid a 35 % YTD rally; obesity and diabetes drugs deliver >$10 billion in quarterly revenue. reuters.Surging demand for weight‑loss drugs, raised revenue forecasts, pipeline of new metabolic treatments, and policy support create a strong.

Final thoughts

The coming holiday‑shortened week could see outsized moves in individual stocks because of low liquidity and a flurry of macro data. Guardian Pharmacy Services, Wayfair, Tutor Perini, Okeanis Eco Tankers and Eli Lilly each have catalysts — ranging from recent earnings beats and guidance raises to booming product demand — that could support further gains. However, investors should remember that strong recent performance can also make stocks susceptible to profit‑taking and volatility. As always, it is prudent to diversify and maintain a long‑term perspective.